Avecho Biotechnology Past Performance
Past criteria checks 0/6
Avecho Biotechnology has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 22.5% annually. Revenues have been declining at an average rate of 20.2% per year.
Earnings growth rate
EPS growth rate
|Pharmaceuticals Industry Growth||22.5%|
|Revenue growth rate||-20.2%|
|Return on equity||-96.6%|
|Last Earnings Update||31 Dec 2022|
Recent past performance updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In GrowthJan 13
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn SituationMay 31
Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth PlansNov 04
We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash WiselyJul 14
We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business GrowthMar 23
We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn RateDec 08
Earnings and Revenue History
Quality Earnings: AVE is currently unprofitable.
Growing Profit Margin: AVE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVE is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.3%).
Return on Equity
High ROE: AVE has a negative Return on Equity (-96.6%), as it is currently unprofitable.